NEW YORK (GenomeWeb) — Inivata announced today it has received a draft Medicare local coverage determination (LCD) through MolDx for its blood-based InVisionFirst-Lung test, a targeted sequencing assay that detects mutations in the blood of non-small cell lung cancer patients to inform treatment selection.
In the draft LCD, Medicare administrative contractor Palmetto GBA has recommended coverage for InVisionFirst-Lung, Inivata said. The draft will go through a public comment period before being finalized and implemented.